Kymera Therapeutics Inc
KYMRHealthcare|Biotechnology|USA
$119.36
+0.34 (+0.28%)
Tangible Book
$18.73
Clinical Trials (14)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT07323654 A Study of KT-621 Administered Orally to Adult Participants With Moderate to Severe Eosinophilic Asthma | Eosinophilic Asthma | P2 | Recruiting | 264 | RCT, Double-blind | KT-621 |
| NCT07677059 A Long-term Study of KT-621 Administered Orally to Participants With Asthma Previously Enrolled in a KT-621 Asthma Study | Asthma (Diagnosis) | P2 | Recruiting | 264 | Open-label | KT-621 |
| NCT07217015 A Study of KT-621 Administered Orally to Participants With Moderate to Severe Atopic Dermatitis | Atopic Dermatitis | P2 | Active | 200 | RCT, Double-blind | KT-621 |
| NCT07629336 SAR447971 First-in-human Study | Hidradenitis, Healthy Volunteers | P1 | Recruiting | 114 | RCT, Double-blind | SAR447971, Placebo |
| NCT07412288 First-in-human Study of Orally Administered KT-579 in Healthy Adult Participants | Healthy Participants | P1 | Recruiting | 96 | RCT, Double-blind | KT-579, Placebo |
| NCT06058156 Phase 2 Study of SAR444656 in Adult Participants With Moderate to Severe Atopic Dermatitis | Atopic Dermatitis | P2 | Terminated | 70 | RCT, Double-blind | SAR444656 (KT-474), Placebo |
| NCT06028230 A Phase 2 Study to Evaluate the Efficacy and Safety of SAR444656 Compared With Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa | Hidradenitis Suppurativa | P2 | Terminated | 70 | RCT, Double-blind | SAR444656 (KT-474), Placebo |
| NCT06673667 First-in-human Study of Orally Administered KT-621 in Healthy Adult Participants | Healthy Participants Study | P1 | Completed | 118 | RCT, Double-blind | KT-621, Placebo |
| NCT05775406 Safety and Clinical Activity of KT-253 in Adult Patients with High Grade Myeloid Malignancies, Acute Lymphocytic Leukemia, Lymphoma, Solid Tumors | Myeloid Malignancies, Acute Lymphocytic Leukemia | P1 | Completed | 52 | Open-label | KT-253 |
| NCT05225584 Safety, PK, PD, Clinical Activity of KT-333 in Adult Patients With Refractory Lymphoma, Large Granular Lymphocytic Leukemia, Solid Tumors | Non Hodgkin Lymphoma (NHL), Peripheral T-cell Lymphoma (PTCL) | P1 | Completed | 56 | Open-label | KT-333 |
| NCT04772885 A Single and Multiple Ascending Dose Trial of KT-474 in Healthy Adult Volunteers and Patients With Atopic Dermatitis (AD) or Hidradenitis Suppurativa (HS) | Healthy Volunteer, Atopic Dermatitis | P1 | Completed | 154 | RCT, Double-blind | KT-474/Placebo, KT-474 |
| NCT06945458 Safety, PK, PD, and Clinical Activity of Orally Administered KT-621 in Adult Patients With Atopic Dermatitis (AD) | Atopic Dermatitis | P1 | Completed | 22 | Open-label | KT-621 |
| NCT05233033 Safety, PK/PD, and Clinical Activity of KT-413 in Adult Patients with Relapsed or Refractory B-cell NHL | Non Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma | P1 | Completed | 7 | Open-label | KT-413 |
| NCT04440410 Evaluation of Cutaneous and Circulating Inflammatory Biomarkers in Hidradenitis Suppurativa and Atopic Dermatitis | Hidradenitis Suppurativa, Dermatitis, Atopic | Completed | 40 | — | — |